Efficacy and Safety of the Neuraminidase Inhibitor Zanamivirin the Treatment of Influenza A and B Virus Infections

Monto, Arnold S.; Fleming, Douglas; Henry, Dan; Groot, Ronald de; Mäkelä, Mika; Klein, Thomas; Elliott, Michael J.; Keene, Oliver N.; Man, Choy

doi:10.1086/314904

Cited by 261 publications

(140 citation statements)

References 39 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…The optimal route of administration and dose of zanamivir in the treatment of naturally acquired in£uenza was explored in a number of studies (Hayden et al 1997;Matsumoto et al 1999;Monto et al 1999a). Their details are summarized in table 1.…”

Section: Clinical Efficacy Studies (A) Experimental In£uenza Infectionmentioning

confidence: 99%

Zanamivir: from drug design to the clinic

Elliott

2001

Phil. Trans. R. Soc. Lond. B

View full text Add to dashboard Cite

The development of the neuraminidase inhibitors has revolutionized the management options for in£u-enza. Zanamivir was the ¢rst such inhibitor to be approved for the treatment of in£uenza in humans. It is delivered by inhalation to the respiratory tract, which is the site of viral replication, in order to ensure immediate antiviral activity. Early treatment with zanamivir in clinical trials rapidly reduced the severity and duration of in£uenza symptoms and associated complications. Furthermore, chemoprophylaxis with zanamivir was shown to be e¡ective in the prevention of in£uenza illness. To date, there is no evidence for the emergence of clinically signi¢cant zanamivir-resistant isolates. In conclusion, zanamivir o¡ers a useful complementary strategy to vaccination in the e¡ective management of in£uenza.

show abstract

Section: Clinical Efficacy Studies (A) Experimental In£uenza Infectionmentioning

confidence: 99%

Zanamivir: from drug design to the clinic

Elliott

2001

Phil. Trans. R. Soc. Lond. B

View full text Add to dashboard Cite

show abstract

“…91,92 The drugs are most effective if administered within the first 30 hours of symptoms in febrile patients and in defined high-risk groups. 93 A recent trial found daily administration of zanamivir for 4 weeks effective in preventing influenza in healthy subjects. Both toxicology 94 and clinical studies 95 have shown this class of compounds to be very safe.…”

Section: Chemoprophylaxis and Pharmacological Treatment Of Influenzamentioning

confidence: 99%

Influenza Infection in Patients Before and After Liver Transplantation

Duchini¹

2000

Liver Transplantation

View full text Add to dashboard Cite

Infection with influenza virus poses specific problems in pediatric and adult liver transplant recipients, both before and after liver transplantation. These include a higher rate of pulmonary and extrapulmonary complications, development of rejection with graft dysfunction, prolonged shedding of influenza virus, and increased drug-resistance. Hepatic decompensation may occur during influenza infection in patients with cirrhosis. Current prophylaxis includes yearly vaccination with trivalent inactivated vaccine. Appropriate diagnosis and prompt treatment of any upper respiratory infections are indicated in these patients. In this review, we describe a case of influenza viral pneumonia in an adult liver transplant recipient, review basic and clinical aspects of influenza infection in this patient population, and discuss current modes of prevention and treatment in detail. (Liver Transpl 2000;6: 531-542.)

show abstract

“…Oseltamivir was developed through the modification of the sialic acid analogue framework (Kim et al, 1997). Many reports have shown that both drugs are highly efficient in the treatment of influenza (Cooper et al, 2003;Hayden et al, 1997;Monto et al, 1999;Nicholson et al, 2000). In recent years, peramivir and laninamivir, which also target NA, have been licensed as anti-influenza drugs (Kubo et al, 2010;Yamashita, 2011).…”

Section: Influenza Therapymentioning

confidence: 99%